Orum Therapeutics announced today that it closed an $84 million Series B financing for its targeted protein degraders for treating cancer. Boston-based Orum’s funding round includes a previously announced $30 million financing, plus another $54 million in new funds led by IMM Investment and joined by new investors KDB Investment and Atinum, among others. Existing […]